Table 2.
Levels of glucagon-stimulated C-peptide (nmol/l) and HbAlc (%, DCCT standard), for all the participants and groups.
| All | Intervention group | Control group | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean±s.d. | Min | Max | Mean±s.d. | Min | Max | Mean±s.d. | Min | Max | |
| C-peptide baseline | 1.45±0.8 | 0.29 | 3.4 | 1.2±0.7 | 0.29 | 3.0 | 1.7±0.9 | 0.65 | 3.4 |
| C-peptide 12 months | 1.35±0.9 | 0.00 | 3.4 | 1.0±0.7 | 0.0 | 3.3 | 1.7±0.9 | 0.53 | 3.4 |
| C-peptide 24 months | 1.17±0.8 | 0.00 | 3.6 | 0.80±0.6 | 0.0 | 1.8 | 1.5±0.9 | 0.37 | 3.6 |
| C-peptide 36 months | 0.99±0.8 | 0.00 | 3.6 | 0.73±0.6 | 0.0 | 2.2 | 1.3±0.9 | 0.32 | 3.6 |
| HbAlc baseline | 7.2±1.3 | 5.2 | 10.1 | 7.3±1.3 | 5.6 | 10.1 | 7.0±1.3 | 5.2 | 9.5 |
| HbAlc 12 months | 6.9±1.2 | 5.2 | 10.9 | 7.1±1.0 | 5.2 | 8.5 | 6.7±1.4 | 5.4 | 10.9 |
| HbAlc 24 months | 7.1±1.2 | 5.1 | 9.3 | 7.4±1.0 | 5.7 | 9.0 | 6.8±1.3 | 5.1 | 9.3 |
| HbAlc 36 months | 7.3±1.1 | 5.3 | 9.8 | 7.2±0.7 | 5.8 | 8.3 | 7.5±1.5 | 5.3 | 9.8 |